\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2021 2021-03-15 (revised: 14 Year 2021 15 March 2021)} \def\TheID{\makeatother } \def\TheDate{2021 2021-03-15} \title{} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Jorge Enrique Díaz-Pinzón} \renewcommand\Authands{ and } \date{\small \em Received: 9 February 2021 Accepted: 2 March 2021 Published: 15 March 2021} \maketitle \begin{abstract} Introduction: SARS (severe acute respiratory syndrome) is the severe stage of COVID-19 caused by massive alveolar damage and progressive respiratory failure; caused by SARS-CoV-2 (SARS coronavirus 2).Objective: To show the behavior of the incidence of COVID-19 and vaccination against SARS-COV-2, between the period between February 17 and September 30, 2021.Methodology: This research was carried out under a cross-sectional study, as a source of information, it was obtained from the national vaccination plan against COVID-19 from the website of the Ministry of Health and Social Protection.Results: An increase in incidence was evidenced over time, the number of vaccines also increased, until June 2021. From July 2021 to September 2021, there was a decrease in the incidence of SARS-CoV-2, as well as the decrease in the application of the number of vaccines. Conclusion:There is a demand for more studies predestined to evaluate the efficacy of vaccination in reducing the transmission of SARS-CoV-2 in Colombia, both at the individual level and at the population level, with a greater longitudinal tracing and in additional populations. \end{abstract} \keywords{incidence, COVID-19, SARS-CoV-2, pandemic, vaccines.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Introduction}]{Introduction}\par ARS (severe acute respiratory syndrome) is the severe stage of COVID-19 caused by massive alveolar damage and progressive respiratory failure; caused by SARS-CoV-2 (SARS coronavirus 2) \hyperref[b0]{1} .\par SARS-CoV-2 belongs to the family Coronaviridae, subfamily Orthocoronaviridae. It is a single-stranded RNA virus, whose genome is around 27-32 kb, which encodes non-structural proteins, such as proteases, helicases, and RNA polymerases: and structural proteins \hyperref[b1]{2,}\hyperref[b2]{3} COVID-19 can be divided into three phases: asymptomatic with or without detectable virus; nonsevere symptomatic with the presence of virus and severe respiratory symptomatic with high viral load \hyperref[b4]{4} . An unresolved question is why some develop serious illness and others do not. Aspects based on the immune response are not enough to explain it, but they will help to understand the behavior of this new pathogen \hyperref[b5]{5} .\par Author: Engineer. Master's in educational technology management, Specialist in Educational Informatics Administration. Mathematics teacher and researcher, institutional affiliation: Secretary of Education of Soacha, Colombia. e-mail: jediazp@unal.edu.co\par The rapid obligation of vaccines against COVID-19 has forced the use of proteomics to search for exclusive antigens of the pathogen in protein S. Thanks to bioinformatics, 933 pentapeptides absent in the human proteome have been recognized, of which 107 peptides are located around protein S and of these 66 peptides are more immunogenic and can be used in the production of a vaccine \hyperref[b6]{6} . The WHO has up to 52 alternative vaccine candidates between platforms based on proteins, RNA, DNA, non-vectors. replicants, replicating vectors, inactivated viruses, attenuated viruses, and virus-like particles. Of all these vaccine inserts, only vaccines made up of RNA and nonreplicating vector have initiated safety studies in humans {\ref 7,8.} To achieve a continued reduction in infection cases \hyperref[b9]{9} multiple countermeasures are needed, including distancing, testing, and tracing, especially considering the recent emergence of new variants of SARS-CoV-2 \hyperref[b10]{10} , such as B.1.1.7 and B.1.351, which are reported to have higher transmissibility \hyperref[b11]{11,}\hyperref[b12]{12} and are likely to cause more severe disease \hyperref[b13]{13} compared to the parent strain. Vaccination alone is not expected to counteract the spread of infection, and a carefully planned vaccination campaign needs to be regulated \hyperref[b14]{14,}\hyperref[b15]{15} The objective of this research is to show the behavior of the incidence of COVID-19 and vaccination against SARS-COV-2, between the period between February 17 to September 30, 2021. \section[{II.}]{II.} \section[{Methodology}]{Methodology}\par This research was carried out under a crosssectional study \hyperref[b16]{[16]}\hyperref[b17]{[17]}\hyperref[b18]{[18]} , the information was obtained from the website of the Ministry of Health and Social Protection \hyperref[b19]{19} of the daily reports of contagion by COVID-19, between the period between January 1, 2021, and September 30, 2021, to calculate the incidence, and from February 17 to September 30, 2021, for vaccination. \section[{III.}]{III.} \section[{Results}]{Results}\par Table \hyperref[tab_0]{1} shows the months between January and September 2021, the new cases of infection by SARS-CoV-2, the vaccines, and the population in Colombia. With the information in columns 2 and 3, the incidence rate was calculated in percentage terms for COVID-19. Source: the autor Figure 1 shows the incidence by months for SARS-CoV-2, between the months of January to September 2021 and the vaccination against COVID-19, between the months of February to September 2021. It describes a similarity in the trend of the incidence lines (blue), and vaccination (orange), that is, while the incidence increases over time, the number of vaccines also increases, this trend is maintained until June. From the month of July to September there is a decrease in the incidence of SARS-CoV-2, as well as the decrease in the application of the number of vaccines. IV. \section[{Source: the author}]{Source: the author} \section[{Conclusions}]{Conclusions}\par From the data analyzed, it is concluded that the incidence of COVID-19 is related to vaccination until June 2021 against SARS-COV-2, that is, as vaccination values increase, Incidence cases due to COVID-19 also increase and a contrary situation from July to September, that is, as vaccination values decrease, incidence cases due to COVID-19 also decrease.\par There is a demand for more studies predestined to evaluate the efficacy of vaccination in reducing the transmission of SARS-CoV-2 in Colombia, both at the individual level and at the population level, with greater longitudinal screening and in additional populations \hyperref[b20]{20} .\par Monitoring the results of vaccinations is essential to understand efficacy, possible decline in immune response over time, and possible adverse effects. Monitoring the effects of these vaccines is possible and much needed. The publication of these data, duly verified, is a priority. For this, it would be very important to follow the vaccinated and check if they suffer from COVID-19 infections, and sequence where appropriate. \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.15781758957654723\textwidth}P{0.1716612377850163\textwidth}P{0.22703583061889251\textwidth}P{0.11905537459283388\textwidth}P{0.1744299674267101\textwidth}} Months\tabcellsep New cases\tabcellsep Population\tabcellsep Incidence\tabcellsep Vaccines\\ January\tabcellsep 451609\tabcellsep 51049498\tabcellsep 0,88\tabcellsep \\ February\tabcellsep 156856\tabcellsep 50597889\tabcellsep 0,31\tabcellsep 130578\\ March\tabcellsep 154687\tabcellsep 50441033\tabcellsep 0,31\tabcellsep 2112814\\ April\tabcellsep 453347\tabcellsep 50286346\tabcellsep 0,9\tabcellsep 2743079\\ May\tabcellsep 543805\tabcellsep 49832999\tabcellsep 1,09\tabcellsep 5105651\\ June\tabcellsep 834526\tabcellsep 49289194\tabcellsep 1,69\tabcellsep 8189621\\ July\tabcellsep 533290\tabcellsep 48454668\tabcellsep 1,1\tabcellsep 9242634\\ August\tabcellsep 123766\tabcellsep 47921378\tabcellsep 0,26\tabcellsep 8021788\\ September\tabcellsep 48191\tabcellsep 47797612\tabcellsep 0,10\tabcellsep 5159042\end{longtable} \par \caption{\label{tab_0}Table 1 :}\end{figure} \footnote{© 2021 Global JournalsBehavior of the Incidence of COVID-19 and Vaccination against SARS-Cov-2 in Colombia} \backmatter \begin{bibitemlist}{1} \bibitem[Colombia et al.]{b21}\label{b21} \textit{}, Colombia , Y Revista Repertorio De Medicina , Cirugía . \xref{http://dx.doi.org/10.31260/RepertMedCir.01217372.1227}{10.31260/RepertMedCir.01217372.1227}. \url{https://doi.org/10.31260/RepertMedCir.01217372.1227} p. . \bibitem[ Asian Pac J Allergy Immunol ()]{b3}\label{b3} \textit{}, \xref{http://dx.doi.org/10.12932/AP-200220-0773}{10.12932/AP-200220-0773}. \textit{Asian Pac J Allergy Immunol} 2020. p. . \bibitem[Abbott and Funk ()]{b12}\label{b12} \textit{\& CMMID COVID-19 Working Group. Números de reproducción del área local y falla del objetivo del gen S}, S Abbott , S Funk . \url{https://cmmid.github.io/topics/covid19/local-r-sgtf.html} 2021. \bibitem[Shi et al. ()]{b4}\label{b4} ‘COVID-19 infection: the perspectives on immune responses’. Y Shi , Y Wang , C Shao , J Huang , J Gan , X Huang . \xref{http://dx.doi.org/10.1038/s41418-020-0530-}{10.1038/s41418-020-0530-}. \textit{Cell Death Differ} 2020. \bibitem[Lozada-Requena and Núñez-Ponce (2020)]{b5}\label{b5} ‘COVID-19: respuestainmune y perspectivas terapéuticas’. I Lozada-Requena , C Núñez-Ponce . \xref{http://dx.doi.org/10.17843/rpmesp.2020.372.5490}{10.17843/rpmesp.2020.372.5490}. \url{https://doi.org/10.17843/rpmesp.2020.372.5490} \textit{Revista Peruana de Medicina Experimental y} Apr-Jun 2020. 37 (2) . \bibitem[Díaz Pinzón ()]{b17}\label{b17} ‘Descripción estadística del COVID-19 según el grupo etario en Colombia’. J E Díaz Pinzón . \xref{http://dx.doi.org/10.31260/RepertMedCir.01217372.1098}{10.31260/RepertMedCir.01217372.1098}. \url{https://doi.org/10.31260/RepertMedCir.01217372.1098} \textit{Revista Repertorio De Medicina Y Cirugía} 2020. p. . \bibitem[Lurie et al. ()]{b8}\label{b8} ‘Developing Covid-19 Vaccines at Pandemic Speed’. N Lurie , M Saville , R Hatchett , J Halton . \xref{http://dx.doi.org/10.1056/NEJMp}{10.1056/NEJMp}. \textit{N Engl J Med [Internet]} 2020. 2005630. \bibitem[Díaz Pinzón ()]{b20}\label{b20} \textit{Dinámica y relación del contagio del COVID-19 después de iniciado el plan de vacunación contra}, J E Díaz Pinzón . el SARS-COV-2 en. 2021. \bibitem[Lucchese ()]{b6}\label{b6} ‘Epitopes for a 2019-nCoV vaccine’. G Lucchese . Doi: 10.1038/ s41423-020-0377-z. \textit{Cell Mol Immunol [Internet]} 2020. \bibitem[Díaz Pinzón ()]{b16}\label{b16} ‘Estimación de la prevalencia del COVID-19 en Colombia’. J E Díaz Pinzón . \xref{http://dx.doi.org/10.31260/RepertMedCir.01217372.1115}{10.31260/RepertMedCir.01217372.1115}. \url{https://doi.org/10.31260/RepertMedCir.01217372.1115} \textit{Revista Repertorio De Medicina Y Cirugía} 2020. p. . \bibitem[Díaz Pinzón ()]{b18}\label{b18} ‘Estimación de la prevalencia del COVID-19 en Colombia’. J E Díaz Pinzón . \xref{http://dx.doi.org/10.31260/RepertMedCir.01217372.1115}{10.31260/RepertMedCir.01217372.1115}. \url{https://doi.org/10.31260/RepertMedCir.01217372.1115} \textit{Revista Repertorio De Medicina Y Cirugía} 2020. p. . \bibitem[Bubar ()]{b14}\label{b14} ‘Estrategias de priorización de la vacuna COVID-19 basad as en modelos por edad y estado serológico’. Bubar . \textit{Science} 2021. 371 p. . \bibitem[Ministerio de Salud y protección Social. Vacunación contra COVID-19]{b19}\label{b19} \textit{Ministerio de Salud y protección Social. Vacunación contra COVID-19}, (citado 05 de octubre de 2021) \bibitem[Ramos et al.]{b15}\label{b15} \textit{Modelización del impacto de las variantes y vacunas del SARS-CoV-2 en la propagación del COVID-Preprint in ResearchGate}, A M Ramos , M Vela-Pérez , Ferrández , Mr , Kubik , B Ivorra . \xref{http://dx.doi.org/10.13140/RG.2.2.32580.24967/2(2021}{10.13140/RG.2.2.32580.24967/2(2021}. \url{https://doi.org/10.13140/RG.2.2.32580.24967/2(2021} \bibitem[Horby ()]{b13}\label{b13} \textit{Nota de NERVTAG sobre la gravedad de B.1.1.7}, P Horby . \url{https://www.gov.uk/govern-ment/publications/nervtag-paper-on-covid-19-variant-of-concern-b117} 2021. \bibitem[Xu et al. ()]{b0}\label{b0} ‘Pathological findings of COVID-19 associated with acute respiratory distress syndrome’. Z Xu , L Shi , Wang , J Zhang , L Huang , C Zhang . \xref{http://dx.doi.org/10.1016/S2213-2600(20)30076-X}{10.1016/S2213-2600(20)30076-X}. \textit{Lancet Respir Med} 2020. 2600 (20) p. . \bibitem[Shanmugaraj et al.]{b2}\label{b2} \textit{Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19}, B Shanmugaraj , K Siriwattananon , K Wangkanont , W Phoolcharoen . COVID-19. \bibitem[Priesemann ()]{b9}\label{b9} ‘Pidiendo un compromiso paneuropeo para una reducción rápida y sostenida de las infecciones por SARS-CoV-2’. V Priesemann . \textit{Lancet} 2021. 397 p. . \bibitem[Zou et al.]{b1}\label{b1} \textit{Singlecell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection}, X Zou , K Chen , J Zou , P Han , J Hao , Z Han . Doi: 10.1007/ s11684-020-0754-0. (Front Med [Internet]. 2020; 1-8) \bibitem[Davies ()]{b11}\label{b11} ‘Transmisibilidad e impacto estimados del linaje B.1.1.7 del SARS-CoV-2 en Inglaterra’. Davies . \textit{Science} 2021. 372 p. 3055. \bibitem[Priesemann ()]{b10}\label{b10} ‘Un plan de acción para la defensa paneuropea contra las nuevas variantes del SARS-CoV-2’. V Priesemann . \textit{Lancet} 2021. 397 p. . \bibitem[Cohen ()]{b7}\label{b7} ‘Vaccine designers take first shots at COVID-19’. J Cohen . \xref{http://dx.doi.org/10.1126/science.368.6486.14}{10.1126/science.368.6486.14}. \textit{Science [Internet]} 2020. 368 (6486) p. . \end{bibitemlist} \end{document}